Penumbra (PEN) Cash from Operations Growth (3y) (2017 - 2026)
Penumbra (PEN) Cash from Operations Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 4.78% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 9.30% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 1.51% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 22.35% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -48.14% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 50.11% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 0.50% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -14.75% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Penumbra | 12.48 Bn | 11.87 Bn | 253.41 Mn | 87.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 87.81% |
| Dec 31, 2025 | 301.42% |
| Sep 30, 2025 | 86.75% |
| Jun 30, 2025 | 46.37% |
| Mar 31, 2025 | 134.22% |
| Dec 31, 2024 | 95.86% |
| Sep 30, 2024 | 15.71% |
| Jun 30, 2024 | 106.70% |
| Mar 31, 2024 | 67.09% |
| Dec 31, 2023 | 168.74% |
| Sep 30, 2023 | 120.28% |
| Jun 30, 2023 | 40.75% |
| Mar 31, 2023 | 61.57% |
| Dec 31, 2022 | -34.54% |
| Sep 30, 2022 | -37.25% |
| Jun 30, 2022 | -183.54% |
| Mar 31, 2022 | -29.72% |
| Dec 31, 2021 | -47.83% |
| Sep 30, 2021 | 51.68% |
| Jun 30, 2021 | -206.15% |